Prof Ken O’Byrne has conducted translational ‘bench-to-bedside-and back-again’ research over the past 25 years with a focus on solid epithelial tumours, in particular in thoracic malignancies.
Ken was the founder of the British Thoracic Oncology Group (BTOG), and founder member of the European thoracic oncology platform (ETOP), and has held committee positions of the International Association for the Study of Lung Cancer (IASLC).
Ken has been involved in the design of and running phase I, II and III clinical trials encouraging the incorporation of biomarker studies, both prognostic and predictive, where possible. He has published over 250 manuscripts in peer reviewed journals and books and has edited 2 books in thoracic oncology.